tropicamide has been researched along with Parkinsonian Disorders in 2 studies
Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tremulous jaw movements were used as a model of parkinsonian tremor in these studies, and the effects of tropicamide were compared with those of the nonselective muscarinic antagonist atropine." | 7.74 | The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. ( Betz, AJ; Burgos, M; McLaughlin, PJ; Salamone, JD; Weber, SM, 2007) |
| " Here, using a model for parkisonian tremor, the pilocarpine-induced tremulous jaw movements (TJMs), we show that the deletion of GPR37 attenuated the TJMs in response to this cholinomimetic." | 3.81 | Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent. ( Ciruela, F; Fernández-Dueñas, V; Gandía, J; Morató, X; Stagljar, I, 2015) |
| "Tremulous jaw movements were used as a model of parkinsonian tremor in these studies, and the effects of tropicamide were compared with those of the nonselective muscarinic antagonist atropine." | 3.74 | The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. ( Betz, AJ; Burgos, M; McLaughlin, PJ; Salamone, JD; Weber, SM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gandía, J | 1 |
| Morató, X | 1 |
| Stagljar, I | 1 |
| Fernández-Dueñas, V | 1 |
| Ciruela, F | 1 |
| Betz, AJ | 1 |
| McLaughlin, PJ | 1 |
| Burgos, M | 1 |
| Weber, SM | 1 |
| Salamone, JD | 1 |
2 other studies available for tropicamide and Parkinsonian Disorders
| Article | Year |
|---|---|
Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent.
Topics: Adenosine A2 Receptor Antagonists; Animals; Jaw; Male; Mice, Inbred C57BL; Mice, Knockout; Movement; | 2015 |
The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.
Topics: Animals; Atropine; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; J | 2007 |